-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Merck and Pfizer announced that the U.SFood and Drugadministration(
FDA) has expanded its application range for the maintenance of local late or metastatic urinary tract cancer (UC) patients with first-line platinum-containing chemotherapyPhoto Source:This approval is based on the results of the PHASE III JAVELIN Bladder 100 study, which showed a significant increase of 7.1 months in primary overall survival (OS) as a first-line maintenance treatment (BSC) compared to the use of best support treatment (BSC) alone, 14.3 months and 21.4 months, respectivelyThe statistically significant improvement in OS resulted in a 31% reduction in the risk of death for the entire patient population"As the firstimmunotherapy that showed a statistically significant improvement in overall survival rates in the first-line treatment of locally advanced or metastatic urethra skin cancer, the FDA approved avelumab as one of the most important advances in the treatment of the disease in 30 years," said Petros Grivas, lead researcher on the JAVELIN Bladder 100 trialplatinum-based chemotherapy is currently the first-line treatment standard for patients with advanced urinary skin cancer with high response rates, but most patients progress earlier than five years of treatment, with only 5% of patients having a pre-metastasis life expectancy of more than five years
